Lv1
32 积分 2023-10-08 加入
A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial
1个月前
已完结
Sacituzumab tirumotecan (Sac-TMT) plus pembrolizumab maintenance therapy in ovarian cancer: Results from the phase 22870-002/SKB264-II-06 study
2个月前
已完结
Sacituzumab tirumotecan (Sac-TMT) plus pembrolizumab in participants with recurrent or metastatic cervical cancer: Results from the phase 22870-002/SKB264-II-06 study
2个月前
已完结
Platinum(II)-Catalyzed Cyclopropanation of Vinyl Arenes and 1,3-Aryl Dienes Employing Aryl Diazirines as Carbene Precursors
2个月前
已完结
Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial
2个月前
已完结
Nickel-catalyzed hydroxymethylation with α-silicon N -methoxyphthalimides via radical Brook rearrangement
4个月前
已完结
Synergistic Nanomedicine Delivering Topoisomerase I Toxin (SN-38) and Inhibitors of Polynucleotide Kinase 3′-Phosphatase (PNKP) for Enhanced Treatment of Colorectal Cancer
5个月前
已完结
Targeting Toll-like Receptors 7, 8, and 9 Inhibition in Systemic Lupus Erythematosus: Therapeutic Advance and Future Directions
6个月前
已完结
Discovery of Highly Selective Inhibitors of Microtubule-Associated Serine/Threonine Kinase-like (MASTL)
7个月前
已完结
皖公网安备34019202002308
